000			05419nam a22003735i 4500
001			286274
003			MX-SnUAN
005			20160429154451.0
007			cr nn 008mamaa
008			150903s2009 xxu| o |||| 0|eng d
020			_a9781441916013 _99781441916013
024	7		_a10.1007/9781441916013 _2doi
035			_avtls000338347
039		9	_a201509030814 _bVLOAD _c201404300343 _dVLOAD _y201402060908 _zstaff
040			_aMX-SnUAN _bspa _cMX-SnUAN _erda
050		4	_aR-RZ
100	1		_aFallon, Padraic G. _eeditor. _9314816
245	1	0	_aPathogen-Derived Immunomodulatory Molecules / _cedited by Padraic G. Fallon.
264		1	_aNew York, NY : _bSpringer New York, _c2009.
300			_brecurso en línea.
336			_atexto _btxt _2rdacontent
337			_acomputadora _bc _2rdamedia
338			_arecurso en línea _bcr _2rdacarrier
347			_aarchivo de texto _bPDF _2rda
490	0		_aAdvances in Experimental Medicine and Biology, _x0065-2598 ; _v666
500			_aSpringer eBooks
505	0		_aBacterial Toxins as Immunomodulators -- Innate Immune Evasion by Staphylococci -- Bacterial Complement Escape -- Modulation of Innate Immune Signalling Pathways by Viral Proteins -- Viral TNF Inhibitors as Potential Therapeutics -- Lipoxins as an Immune-Escape Mechanism -- Immunomodulatory Activity and Therapeutic Potential of the Filarial Nematode Secreted Product, ES-62 -- Helminth-Derived Immunomodulatory Molecules -- Fungal-Derived Immune Modulating Molecules -- The Immunosuppresive Tick Salivary Protein, Salpl5 -- The Serpin Saga; Development of a New Class of Virus Derived Anti-Inflammatory Protein Immunotherapeutics -- Helminthic Therapy: Using Worms to Treat Immune-Mediated Disease -- Chemokine Binding Proteins Encoded by Pathogens.
520			_aPathogen-Derived Immunomodulatory Molecules is a book title that may require some explanation. Pathogens that are present today have evolved following a long association with man and have developed unique strategies that have been optimized by natural selection to subvert the host immunity. As we approach the 200th anniversary of Charles Darwin’s birth, it is appropriate to appreciate that Darwin recognized that pathogens (infections) play a significant and potent role in natural selection, encompassed by the concept “infection begets natural selection”. This book therefore examines the molecules that pathogens produce, which can modulate or usurp the functions of the immune system. The idea of using molecules from pathogens as a therapeutic is an ancient concept in medicine. Such a strategy is exemplified by vaccination, with pathogen molecules employed to induce protective immunity against the given or related species of pathogen. The following chapters explore the concept of using pathogen-derived immune modulating molecules as a therapy. In doing so, they may provide the drug cabinet of the future for treating a spectrum of unrelated disease. Herein, a range of immune modulating molecules or strategies from various pathogens is examined in one volume. The intention of the book was to have chapters addressing immunomodulating molecules from different pathogens. The range of pathogens considered includes bacteria (chapters by Williams, van Strijp and Rooijakkers), viruses (chapters by Bowie, McFadden), protozoan parasites (Aliberti), helminths (Harnett, Fallon), fungi (Sorrell) and parasitic ticks (Anguita). Chapters also address specific immunomodulatory molecules or strategies. The diversity of aspects addressed in the book is highlighted by Lucas and colleagues review of the ‘saga’ of viral serine proteinase inhibitors, with a focus on Serp-1, the first new generation of pathogen immunomodulatory molecule currently in clinical trials. While Elliott and Weinstock have contributed a provocative chapter exploring the use of live parasitic helminth infections as a therapeutic strategy for immune-mediated diseases; indeed trials have already been completed for such an approach. With respect to pathogens usurping an immune pathway, Alcami and colleagues here reviewed the growing number of pathogens that have evolved a range of molecules that can modify many aspects of the chemokine system. This book is timely due to the need to expand the horizons of conventional drug discovery. A trend in the biopharmaceutical pipeline of fewer drugs to market is illustrated by USA FDA in 2007 approving the lowest number of new molecular entities since 1983. As the drug discovery and development industry broadens its search for new drugs to less traditional strategies, this book will be a reference to the potential for exploiting pathogen as a source of the anti-inflammatory drugs of the future. Finally, this book whets the appetite for the reader, whether in academia or industry, to explore opportunities for exploiting pathogens for the discovery of new processes in immunobiology and, ultimately, for development of new therapies for human inflammatory diseases.
590			_aPara consulta fuera de la UANL se requiere clave de acceso remoto.
710	2		_aSpringerLink (Servicio en línea) _9299170
776	0	8	_iEdición impresa: _z9781441916006
856	4	0	_uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-1-4419-1601-3 _zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942			_c14
999			_c286274 _d286274